Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a simple drug combo stop Post-Surgery heart flutters?

NCT ID NCT02750319

Prevention Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding N-Acetylcysteine (NAC) to the standard drug amiodarone can better prevent atrial fibrillation (a type of irregular heartbeat) in people at high risk after major chest surgery. About 184 adults having lung or esophagus surgery will be randomly assigned to get either the combo or amiodarone alone. The goal is to see if the combo reduces dangerous heart rhythm problems within the first week after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

184 people

The number who actually took part.

Started

Apr 2016

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients ≥18 years old scheduled for elective thoracic surgery (segmentectomy, lobectomy or bi-lobectomy, pneumonectomy or esophagectomy) and meeting one of the four following risk criteria: * 1\. Female \& BNP ≥ 25pg/ml (no age limit) * 2\. Male gender \<75 \& BNP ≥ 25pg/ml * 3\. Male- age ≥75 (No BNP limit) * 4\. History of prior AF * Patients in sinus rhythm. * Patients with stable respiratory status (no respiratory distress). * Patients capable of providing written, informed consent. Exclusion Criteria: * Patients scheduled for extrapleural pneumonectomy. * Hemodynamically unstable patients (not in cardiogenic shock or having an acute MI). * Patients with 2nd or 3rd degree atrioventricular (AV) block. * Patients with hypersensitivity to amiodarone or NAC. * Patients already taking class Ic or III antiarrhythmic drugs. * Hepatic insufficiency (≤2 times the upper normal limit of transaminase levels). * Renal insufficiency (creatinine ≥2.0 mg/dl). * Known pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation in high risk patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation in high risk patients Thoracic surgery

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Consent only)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Bergen (Consent only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Consent only)

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Consent only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Consent only)

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Rockville Centre (Consent only)

    Rockville Centre, New York, 11570, United States

  • Memorial Sloan Kettering Westchester (Consent only)

    Harrison, New York, 10604, United States

  • University of Washington School of Medicine in St. Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.